Efficacy of Neuromuscular Blocking Drugs Information Collection Form

COMPANY REFERENCE NUMBER:									
1. REPORTER'S DETAILS				2. PATIENT'S DETAILS					
Name:				Ini	itials:		☐ Male	☐ Female	
Role: _				Ag	ge:				
Address:				or			Weight	kg	
				Date of Birth://			Height	cm	
3a. N	euromi	uscular Bl	ocking Agent administ		d (please de	etail each dose or	measurement on	a new line)	
Date	Time Train of Neuromuscular block Four agent Ratio		ng	Batch Number	Dose given (mg/kg) / infusion rate	(e.g. normal /	Indication (e.g. normal / rapid sequence induction)		
3b. Has the above product been consistently stored in line with section 6.4 of the SmPC?		in	Yes	NI	No (provide details)			
3c. Was Train Of Four (TOF) monitoring undertaken?				No	NI	Yes (provide detain	ils)		
	details o		s NOT undertaken, pleas legree of relaxation was	se					

4a. Plo	ease provide details of the procedure that the	he patient underwent			
4b. If	any of the below procedural complications	occurred (*) please prov	ide additional de	tails.	
Was th	e procedure completed successfully?		Yes	No *	NI
Was in	subation of the patient successful?		Yes	No *	NI
Was ex	tubation (and return to spontaneous breathing) of	the patient successful?	Yes	No *	NI
Was an	y residual curarisation or recurarisation observed?	?	Yes *	No	NI
Were a	ny other adverse events observed?		Yes *	No	NI
-	Is the patient considered to be recovered from th	ese events?	Yes	No *	NI
Was th	e patient's hospitalisation prolonged or further trea	atment needed?	Yes *	No	NI
Furthe	r details:				
4c	. Concomitant medication given as pa	rt of the anaesthesia pro	tocol and surgica	l procedu	re
Time	Drug name	Indication	Dose or Rate	of Ro	oute of
			administratio	n admii	<u>nistration</u>
4d	. Reversal agents administered				
Time	Drug name	Indication	Dose or Rate		oute of
			administratio	n admii	nistration

5a. Please confirm the following details below.	ng medical history for the patient	and where c	onfirmed (*)	provide addit	tional
Muscle disorders (e.g. myasthenia gra	avis)		Yes *	No	N.
Cardiovascular disease			Yes *	No	N.
Neurological disorders (e.g. motor ne		Yes *	No	N	
Liver disorders	Yes *	No	N		
Kidney disorders	Yes *	No	N		
Severe burns to skin or inhalation bur	Yes *	No	N		
Is the patient a smoker?		Yes *	No	N	
Any other relevant medical history	Yes *	No	N		
Further details:					
5b. Please confirm ALL co where confirmed provide additional confirmed pro	ncomitant medication taken by the onal details below.	he patient wi	thin the LAS	T 6 MONTHS	S and
Corticosteroids			Yes *	No	N.
Antibiotics (e.g. aminoglycosides, lin acylamino-penicillins, metronidazole)		Yes *	No	N	
Anticonvulsants (e.g. phenytoin, carb	amazepine)		Yes *	No	N.
Phosphodiesterase inhibitors (e.g. the	ophylline)		Yes *	No	N
Calcium channel blockers		Yes *	No	N	
β -blockers (e.g. propranolol)	Yes *	No	N		
Anti-arrhythmic agents (e.g. lidocaine	Yes *	No	N		
Diuretics (thiazide diuretics, furosemi		Yes *	No	N	
Local anaesthetics including via epidu	Yes *	No	N		
Halogenated inhalational anaesthetics	Yes *	No	N		
Drugs containing calcium, magnesium		Yes *	No	N	
Any other concomitant medication		Yes *	No	N.	
		l' 4' I	Yes* was indi	icated above:	
Please provide additi	ional detail for any concomitant med	iication where			
Please provide additi Drug name	ional detail for any concomitant med Indication	Date started	Date stopped	Total Daily Dose	Route
<u> </u>	·	Date	Date	Total Daily	Route
<u> </u>	·	Date	Date	Total Daily	Route
<u> </u>	·	Date	Date	Total Daily	Route